Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Open-label Single Agent Study of SUPLEXA Therapeutic Cells in Patients With Metastatic Solid Tumours and Haematologic Malignancies

NCT05237206 is registered in ClinicalTrials.gov with Alloplex Biotherapeutics Inc as lead sponsor.

NCT NCT05237206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05237206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Open-label Single Agent Study of SUPLEXA Therapeutic Cells in Patients With Metastatic Solid Tumours and Haematologic Malignancies
Lead sponsor
Alloplex Biotherapeutics Inc
Phase
Phase 1
Overall status
Completed
Start date
April 28, 2022
Completion date
July 23, 2024
Enrollment
46 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

oncology